Methods to predict heart failure in diabetes patients

References

• Hostalek U. Global epidemiology of prediabetes - present and future perspectives. Clin Diabetes Endocrinol. 2019;5(1):5. doi: 10.1186/s40842-019-0080-0
   PubMedGoogle Scholar
• Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabet Res Clin Pract. 2022;183:109119. doi: 10.1016/j.diabres.2021.109119
   PubMed Web of Science ®Google Scholar
• Volaco A, Cavalcanti AM, Filho RP, et al. Socioeconomic status: the missing link between obesity and diabetes mellitus? Curr Diabetes Rev. 2018;14(4):321–326. doi: 10.2174/1573399813666170621123227
   PubMed Web of Science ®Google Scholar
• Chang WW, Zhang L, Wen LY, et al. Association between the MCP-1 -2518 a > g (rs1024611) polymorphism and susceptibility to type 2 diabetes mellitus and diabetic nephropathy: a meta-analysis. BMC Endocr Disord. 2023;23(1):267. doi: 10.1186/s12902-023-01514-z
   PubMed Web of Science ®Google Scholar
• Menon S, Rossi R, Nshimyumukiza L, et al. Convergence of a diabetes mellitus, protein energy malnutrition, and TB epidemic: the neglected elderly population. BMC Infect Dis. 2016;16(1):361. doi: 10.1186/s12879-016-1718-5
   PubMedGoogle Scholar
• Mehta P, Gasparyan AY, Zimba O, et al. Interplay of diabetes mellitus and rheumatic diseases amidst the COVID-19 pandemic: influence on the risk of infection, outcomes, and immune responses. Clin Rheumatol. 2022;41(12):3897–3913. doi: 10.1007/s10067-022-06365-y
   PubMed Web of Science ®Google Scholar
• Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Curr Cardiol Rep. 2019;21(4):21. doi: 10.1007/s11886-019-1107-y
   PubMed Web of Science ®Google Scholar
• Berezin AE, Berezin AA, Lichtenauer M. Emerging role of adipocyte dysfunction in inducing heart failure among obese patients with prediabetes and known diabetes mellitus. Front Cardiovasc Med. 2020;7:583175. doi: 10.3389/fcvm.2020.583175
   PubMed Web of Science ®Google Scholar
• Park JJ. Epidemiology, pathophysiology, diagnosis and treatment of heart failure in diabetes. Diabetes Metab J. 2021;45(2):146–157. doi: 10.4093/dmj.2020.0282
   PubMed Web of Science ®Google Scholar
• Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus. Circ Res. 2019;124(1):121–141. doi: 10.1161/CIRCRESAHA.118.311371
   PubMed Web of Science ®Google Scholar
• Aune D, Schlesinger S, Neuenschwander M, et al. Diabetes mellitus, blood glucose and the risk of heart failure: a systematic review and meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2018;28(11):1081–1091. doi: 10.1016/j.numecd.2018.07.005
   PubMed Web of Science ®Google Scholar
• Kodama S, Fujihara K, Horikawa C, et al. Diabetes mellitus and risk of new-onset and recurrent heart failure: a systematic review and meta-analysis. ESC Heart Fail. 2020;7(5):2146–2174. doi: 10.1002/ehf2.12782
   PubMed Web of Science ®Google Scholar
• Dunlay SM, Givertz MM, Aguilar D, et al. American heart association heart failure and transplantation committee of the council on clinical cardiology; council on cardiovascular and stroke nursing; and the heart failure society of america. type 2 diabetes mellitus and heart failure: a scientific statement from the American heart association and the heart failure society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140(7):e294–e324. doi: 10.1161/CIR.0000000000000691
   PubMed Web of Science ®Google Scholar
• Bozkurt B, Aguilar D, Deswal A, et al. American heart association heart failure and transplantation committee of the council on clinical cardiology; council on cardiovascular surgery and anesthesia; council on cardiovascular and stroke nursing; council on hypertension; and council on quality and outcomes research. contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American heart association. Circulation. 2016;134(23):e535–e78. doi: 10.1161/CIR.0000000000000450
   PubMed Web of Science ®Google Scholar
• Dunlay SM, Killian JM, Mccoy RG, et al. Diabetes mellitus in advanced heart failure. J Card Fail. 2022;28(3):503–508. doi: 10.1016/j.cardfail.2021.09.016
   PubMed Web of Science ®Google Scholar
• Sharma A, Cooper LB, Fiuzat M, et al. Antihyperglycemic therapies to treat patients with heart failure and diabetes mellitus. JACC Heart Fail. 2018;6(10):813–822. doi: 10.1016/j.jchf.2018.05.020
   PubMed Web of Science ®Google Scholar
• Malik A, Garland E, Drozd M, et al. Diabetes mellitus and the causes of hospitalization in people with heart failure. Diab Vasc Dis Res. 2022;19(1):14791641211073943. doi: 10.1177/14791641211073943
   Web of Science ®Google Scholar
• Jankauskas SS, Kansakar U, Varzideh F, et al. Heart failure in diabetes. Metabolism. 2021;125:154910. doi: 10.1016/j.metabol.2021.154910
   PubMed Web of Science ®Google Scholar
• Marrano N, Biondi G, Borrelli A, et al. Type 2 diabetes and alzheimer’s disease: the emerging role of cellular lipotoxicity. Biomolecules. 2023;13(1):183. doi: 10.3390/biom13010183
   PubMed Web of Science ®Google Scholar
• Monnier L, Colette C, Schlienger JL, et al. Glucocentric risk factors for macrovascular complications in diabetes: glucose ‘legacy’ and ‘variability’-what we see, know and try to comprehend. Diabetes metab. 2019;45(5):401–408. doi: 10.1016/j.diabet.2019.01.007
   PubMed Web of Science ®Google Scholar
• Berezin A. Metabolic memory phenomenon in diabetes mellitus: achieving and perspectives. Diabetes Metab Syndr. 2016;10(2 Suppl 1):S176–83. doi: 10.1016/j.dsx.2016.03.016
   PubMed Web of Science ®Google Scholar
• Singh A, Kukreti R, Saso L, et al. Mechanistic insight into oxidative stress-triggered signaling pathways and type 2 diabetes. Molecules. 2022;27(3):950. doi: 10.3390/molecules27030950
   PubMed Web of Science ®Google Scholar
• Rocha M, Diaz-Morales N, Rovira-Llopis S, et al. Mitochondrial dysfunction and endoplasmic reticulum stress in diabetes. Curr Pharm Des. 2016;22(18):2640–2649. doi: 10.2174/1381612822666160209152033
   PubMed Web of Science ®Google Scholar
• Wimmer RA, Leopoldi A, Aichinger M, et al. Human blood vessel organoids as a model of diabetic vasculopathy. Nature. 2019;565(7740):505–510. doi: 10.1038/s41586-018-0858-8
   PubMed Web of Science ®Google Scholar
• Yuan Q, Sun Y, Yang F, et al. CircRNA DICAR as a novel endogenous regulator for diabetic cardiomyopathy and diabetic pyroptosis of cardiomyocytes. Signal Transduct Target Ther. 2023;8(1):99. doi: 10.1038/s41392-022-01306-2
   PubMed Web of Science ®Google Scholar
• Chen Y, Xin Y, Cheng Y, et al. Mitochondria-endoplasmic reticulum contacts: the promising regulators in diabetic cardiomyopathy. Oxid Med Cell Longevity. 2022;2022:1–13. doi: 10.1155/2022/2531458
   Web of Science ®Google Scholar
• van den Oever IA, Raterman HG, Nurmohamed MT, et al. Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm. 2010;2010:1–15. doi: 10.1155/2010/792393
   Web of Science ®Google Scholar
• Makowski LM, Leffers M, Waltenberger J, et al. Transforming growth factor-β1 signaling triggers vascular endothelial growth factor resistance and monocyte dysfunction in type 2 diabetes mellitus. J Cell Mol Med. 2021;25(11):5316–5325. doi: 10.1111/jcmm.16543
   PubMed Web of Science ®Google Scholar
• Khalid M, Petroianu G, Adem A. Advanced glycation end products and diabetes mellitus: mechanisms and perspectives. Biomolecules. 2022;12(4):542. doi: 10.3390/biom12040542
   PubMed Web of Science ®Google Scholar
• Al Kury LT, Sardu C. Calcium homeostasis in ventricular myocytes of diabetic cardiomyopathy. J Diabetes Res. 2020;2020:1–12. doi: 10.1155/2020/1942086
   Web of Science ®Google Scholar
• Komici K, Femminella GD, de Lucia C, et al. Predisposing factors to heart failure in diabetic nephropathy: a look at the sympathetic nervous system hyperactivity. Aging Clin Exp Res. 2019;31(3):321–330. doi: 10.1007/s40520-018-0973-2
   PubMed Web of Science ®Google Scholar
• Pan KL, Hsu YC, Chang ST, et al. The role of cardiac fibrosis in diabetic cardiomyopathy: from pathophysiology to clinical diagnostic tools. Int J Mol Sci. 2023;24(10):8604. doi:10.3390/ijms24108604
   PubMed Web of Science ®Google Scholar
• Lafuse WP, Wozniak DJ, Rajaram MVS. Role of cardiac macrophages on cardiac inflammation, fibrosis and tissue repair. Cells. 2020;10(1):51. doi: 10.3390/cells10010051
   PubMed Web of Science ®Google Scholar
• Wang M, Li Y, Li S, et al. Endothelial dysfunction and diabetic cardiomyopathy. Front Endocrinol. 2022;13:851941. doi: 10.3389/fendo.2022.851941
   PubMed Web of Science ®Google Scholar
• Prandi FR, Evangelista I, Sergi D, et al. Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants. Heart Fail Rev. 2023;28(3):597–606. doi: 10.1007/s10741-021-10200-y
   PubMed Web of Science ®Google Scholar
• Kolaczynski JW, Caro JF. Insulin-like growth factor-1 therapy in diabetes: physiologic basis, clinical benefits, and risks. Ann Intern Med. 1994;120(1):47–55. doi: 10.7326/0003-4819-120-1-199401010-00009
   PubMed Web of Science ®Google Scholar
• Mohamed-Ali V, Pinkney J. Therapeutic potential of insulin-like growth factor-1 in patients with diabetes mellitus. Treat Endocrinol. 2002;1(6):399–410. doi: 10.2165/00024677-200201060-00005
   PubMedGoogle Scholar
• Halim M, Halim A. The effects of inflammation, aging and oxidative stress on the pathogenesis of diabetes mellitus (type 2 diabetes). Diabetes Metab Syndr. 2019;13(2):1165–1172. doi:10.1016/j.dsx.2019.01.040
   PubMed Web of Science ®Google Scholar
• Galley JC, Singh S, Awata WMC, et al. Adipokines: deciphering the cardiovascular signature of adipose tissue. Biochem Pharmacol. 2022;206:115324. doi: 10.1016/j.bcp.2022.115324
   PubMed Web of Science ®Google Scholar
• Berezin AE, Berezin AA. Impaired function of fibroblast growth factor 23/Klotho protein axis in prediabetes and diabetes mellitus: promising predictor of cardiovascular risk. Diabetes Metab Syndr. 2019;13(4):2549–2556. doi: 10.1016/j.dsx.2019.07.018
   PubMed Web of Science ®Google Scholar
• Verma S, Szmitko PE. The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosis. Can J Cardiol. 2006;22(Suppl B):12B–17B. doi: 10.1016/s0828-282x(06)70981-3
   PubMedGoogle Scholar
• Qi Y, Zhu Q, Zhang K, et al. Activation of Foxo1 by insulin resistance promotes cardiac dysfunction and β-myosin heavy chain gene expression. Circ Heart Fail. 2015;8(1):198–208. doi: 10.1161/CIRCHEARTFAILURE.114.001457
   PubMed Web of Science ®Google Scholar
• Ren Y, Zhao H, Yin C, et al. Adipokines, hepatokines and myokines: focus on their role and molecular mechanisms in adipose tissue inflammation. Front Endocrinol. 2022;13:873699. doi: 10.3389/fendo.2022.873699
   PubMed Web of Science ®Google Scholar
• Berezin AE, Samura TA, Kremzer AA, et al. An association of serum vistafin level and number of circulating endothelial progenitor cells in type 2 diabetes mellitus patients. Diabetes Metab Syndr. 2016;10(4):205–212. doi: 10.1016/j.dsx.2016.06.008
   PubMedGoogle Scholar
• de Oliveira Dos Santos AR, de Oliveira Zanuso B, Miola VFB, et al. Adipokines, myokines, and hepatokines: crosstalk and metabolic repercussions. Int J Mol Sci. 2021;22(5):2639. doi: 10.3390/ijms22052639
   PubMed Web of Science ®Google Scholar
• Marx N, Federici M, Schütt K, et al. ESC Scientific Document Group. ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–4140. doi: 10.1093/eurheartj/ehad192
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79(17):e263–e421. doi: 10.1016/j.jacc.2021.12.012
   PubMed Web of Science ®Google Scholar
• Segar MW, Vaduganathan M, Patel KV, et al. Machine learning to predict the risk of incident heart failure hospitalization among patients with diabetes: the WATCH-DM risk score. Diabetes Care. 2019;42(12):2298–2306. doi: 10.2337/dc19-0587
   PubMed Web of Science ®Google Scholar
• Elharram M, Ferreira JP, Huynh T, et al. Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: validation of the thrombolysis in myocardial infarction risk score for heart failure in diabetes (TRS-HFDM) in patients in the ACCORD trial. Diab Obes Metab. 2021;23(3):782–790. doi: 10.1111/dom.14283
   PubMed Web of Science ®Google Scholar
• Basu S, Sussman JB, Berkowitz SA, et al. Validation of risk equations for complications of type 2 diabetes (RECODe) using individual participant data from diverse longitudinal cohorts in the U.S. Diabetes Care. 2018;41(3):586–595. doi: 10.2337/dc17-2002
   PubMed Web of Science ®Google Scholar
• Segar MW, Patel KV, Hellkamp AS, et al. Validation of the WATCH-DM and TRS-HFDM risk scores to predict the risk of incident hospitalization for heart failure among adults with type 2 diabetes: a multicohort analysis. J Am Heart Assoc. 2022;11(11):e024094. doi: 10.1161/JAHA.121.024094
   PubMed Web of Science ®Google Scholar
• Kostopoulos G, Doundoulakis I, Toulis KA, et al. Prognostic models for heart failure in patients with type 2 diabetes: a systematic review and meta-analysis. Heart. 2023;109(19):1436–1442. doi: 10.1136/heartjnl-2022-322044
   PubMed Web of Science ®Google Scholar
• Marwick TH, Shah SJ, Thomas JD. Myocardial strain in the assessment of patients with heart failure: a review. JAMA Cardiol. 2019;4(3):287–294. doi: 10.1001/jamacardio.2019.0052
   PubMed Web of Science ®Google Scholar
• Tao Y, Wang W, Zhu J, et al. H2FPEF score predicts 1-year rehospitalisation of patients with heart failure with preserved ejection fraction. Postgrad Med J. 2021;97(1145):164–167. doi: 10.1136/postgradmedj-2019-137434
   PubMed Web of Science ®Google Scholar
• Sueta D, Yamamoto E, Nishihara T, et al. H2FPEF score as a prognostic value in HFpEF patients. Am J Hypertens. 2019;32(11):1082–1090. doi: 10.1093/ajh/hpz108
   PubMed Web of Science ®Google Scholar
• Carluccio E, Dini FL, Biagioli P, et al. The ‘Echo Heart Failure Score’: an echocardiographic risk prediction score of mortality in systolic heart failure. Eur J Heart Fail. 2013;15(8):868–876. doi: 10.1093/eurjhf/hft038
   PubMed Web of Science ®Google Scholar
• D’Alto M, Romeo E, Argiento P, et al. A simple echocardiographic score for the diagnosis of pulmonary vascular disease in heart failure. J Cardiovasc Med (Hagerstown). 2017;18(4):237–243. doi: 10.2459/JCM.0000000000000485
   PubMed Web of Science ®Google Scholar
• Yang HH, Li FR, Chen ZK, et al. Duration of diabetes, glycemic control, and risk of heart failure among adults with diabetes: a cohort study. J Clin Endocrinol Metab. 2023;108(5):1166–1172. doi: 10.1210/clinem/dgac642
   PubMed Web of Science ®Google Scholar
• Ghouse J, Isaksen JL, Skov MW, et al. Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes. Diab Obes Metab. 2020;22(2):231–242. doi: 10.1111/dom.13891
   PubMed Web of Science ®Google Scholar
• Seferovic JP, Tesic M, Seferovic PM, et al. Increased left ventricular mass index is present in patients with type 2 diabetes without ischemic heart disease. Sci Rep. 2018;8(1):926. doi: 10.1038/s41598-018-19229-w
   PubMedGoogle Scholar
• Patel KV, Khan MS, Segar MW, et al. Optimal cardiometabolic health and risk of heart failure in type 2 diabetes: an analysis from the Look AHEAD trial. Eur J Heart Fail. 2022;24(11):2037–2047. doi: 10.1002/ejhf.2723
   PubMed Web of Science ®Google Scholar
• Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–644. doi: 10.1056/NEJMoa1800256
   PubMed Web of Science ®Google Scholar
• Kong MG, Jang SY, Jang J, et al. Impact of diabetes mellitus on mortality in patients with acute heart failure: a prospective cohort study. Cardiovasc Diabetol. 2020;19(1):49. doi: 10.1186/s12933-020-01026-3
   PubMedGoogle Scholar
• Li S, Nemeth I, Donnelly L, et al. Visit-to-visit HbA1c variability is associated with cardiovascular disease and microvascular complications in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2020;43(2):426–432. doi: 10.2337/dc19-0823
   PubMed Web of Science ®Google Scholar
• Lichtenauer M, Jirak P, Paar V, et al. Heart failure and diabetes mellitus: biomarkers in risk stratification and prognostication. Appl Sci. 2021;11(10):4397. doi: 10.3390/app11104397
   Google Scholar
• Ciardullo S, Rea F, Cannistraci R, et al. NT-ProBNP and mortality across the spectrum of glucose tolerance in the general US population. Cardiovasc Diabetol. 2022;21(1):236. doi: 10.1186/s12933-022-01671-w
   PubMed Web of Science ®Google Scholar
• Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. Int J Mol Sci. 2019;20(8):1820. doi: 10.3390/ijms20081820
   PubMed Web of Science ®Google Scholar
• Huelsmann M, Neuhold S, Strunk G, et al. NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J. 2008;29(18):2259–2264. doi: 10.1093/eurheartj/ehn334
   PubMed Web of Science ®Google Scholar
• Neuhold S, Resl M, Huelsmann M, et al. Repeat measurements of glycated haemoglobin A(1c) and N-terminal pro-B-type natriuretic peptide: divergent behaviour in diabetes mellitus. Eur J Clin Invest. 2011;41(12):1292–1298. doi: 10.1111/j.1365-2362.2011.02539.x
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 steering committee and investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. doi: 10.1056/NEJMoa1307684
   PubMed Web of Science ®Google Scholar
• Ohkuma T, Jun M, Woodward M, et al. ADVANCE Collaborative Group. Cardiac stress and inflammatory markers as predictors of heart failure in patients with type 2 diabetes: the ADVANCE trial. Diabetes Care. 2017;40(9):1203–1209. doi: 10.2337/dc17-0509
   PubMed Web of Science ®Google Scholar
• Huelsmann M, Neuhold S, Resl M, et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol. 2013;62(15):1365–1372. doi: 10.1016/j.jacc.2013.05.069
   PubMed Web of Science ®Google Scholar
• Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310(1):66–74. doi: 10.1001/jama.2013.7588
   PubMed Web of Science ®Google Scholar
• Pandey A, Vaduganathan M, Patel KV, et al. Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes. JACC Heart Fail. 2021;9(3):215–223. doi: 10.1016/j.jchf.2020.10.013
   PubMed Web of Science ®Google Scholar
• Berg DD, Wiviott SD, Scirica BM, et al. A biomarker-based score for risk of hospitalization for heart failure in patients with diabetes. Diabetes Care. 2021;44(11):2573–2581. doi: 10.2337/dc21-1170
   PubMed Web of Science ®Google Scholar
• Segar MW, Khan MS, Patel KV, et al. Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. Eur J Heart Fail. 2022;24(1):169–180. doi: 10.1002/ejhf.2375
   PubMed Web of Science ®Google Scholar
• Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624–638. doi: 10.1161/CIRCRESAHA.117.311586
   PubMed Web of Science ®Google Scholar
• Segar MW, Khan MS, Patel KV, et al. Prevalence and prognostic implications of diabetes with cardiomyopathy in community-dwelling adults. J Am Coll Cardiol. 2021;78(16):1587–1598. doi: 10.1016/j.jacc.2021.08.020
   PubMed Web of Science ®Google Scholar
• Iwakura K, Onishi T, Okamura A, et al. PURSUIT-HFpEF investigators. The WATCH-DM risk score estimates clinical outcomes in type 2 diabetic patients with heart failure with preserved ejection fraction. Sci Rep. 2024;14(1):1746. doi: 10.1038/s41598-024-52101-8
   PubMed Web of Science ®Google Scholar
• Sandoval Y, Apple FS, Saenger AK, et al. 99th percentile upper-reference limit of cardiac troponin and the diagnosis of acute myocardial infarction. Clin Chem. 2020;66(9):1167–1180. doi: 10.1093/clinchem/hvaa158
   PubMed Web of Science ®Google Scholar
• Katrukha IA, Katrukha AG. Myocardial injury and the release of troponins I and T in the blood of patients. Clin Chem. 2021;67(1):124–130. doi: 10.1093/clinchem/hvaa281
   PubMed Web of Science ®Google Scholar
• Selvin E, Lazo M, Chen Y, et al. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation. 2014;130(16):1374–1382. doi: 10.1161/CIRCULATIONAHA.114.010815
   PubMed Web of Science ®Google Scholar
• Yan I, Börschel CS, Neumann JT, et al. High-sensitivity cardiac troponin i levels and prediction of heart failure: results from the BiomarCaRE consortium. JACC Heart Fail. 2020;8(5):401–411. doi: 10.1016/j.jchf.2019.12.008
   PubMed Web of Science ®Google Scholar
• Alonso N, Lupón J, Barallat J, et al. Impact of diabetes on the predictive value of heart failure biomarkers. Cardiovasc Diabetol. 2016;15(1):151. doi: 10.1186/s12933-016-0470-x
   PubMedGoogle Scholar
• Rørth R, Jhund PS, Kristensen SL, et al. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. Eur J Heart Fail. 2019;21(1):40–49. doi: 10.1002/ejhf.1359
   PubMed Web of Science ®Google Scholar
• Jia X, Sun W, Hoogeveen RC, et al. High-sensitivity troponin i and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study. Circulation. 2019;139(23):2642–2653. doi: 10.1161/CIRCULATIONAHA.118.038772
   PubMed Web of Science ®Google Scholar
• Florido R, Kwak L, Echouffo-Tcheugui JB, et al. Obesity, galectin-3, and incident heart failure: the ARIC study. J Am Heart Assoc. 2022;11(9):e023238. doi: 10.1161/JAHA.121.023238
   PubMed Web of Science ®Google Scholar
• Baccouche BM, Mahmoud MA, Nief C, et al. Galectin-3 is associated with heart failure incidence: a meta-analysis. Curr Cardiol Rev. 2023;19(3):e171122211004. doi: 10.2174/1573403X19666221117122012
   PubMed Web of Science ®Google Scholar
• Aguilar D, Sun C, Hoogeveen RC, et al. Levels and change in galectin-3 and association with cardiovascular events: the ARIC study. J Am Heart Assoc. 2020;9(13):e015405. doi: 10.1161/JAHA.119.015405
   PubMed Web of Science ®Google Scholar
• de Boer RA, Edelmann F, Cohen-Solal A, et al. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail. 2013;15(10):1095–1101. doi: 10.1093/eurjhf/hft077
   PubMed Web of Science ®Google Scholar
• Djoussé L, Matsumoto C, Petrone A, et al. Plasma galectin 3 and heart failure risk in the P hysicians’ H ealth S tudy. European J Heart Fail. 2014;16(3):350–354. doi: 10.1002/ejhf.21
   PubMed Web of Science ®Google Scholar
• Chen A, Hou W, Zhang Y, et al. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. Int J Cardiol. 2015;182:168–170. doi:10.1016/j.ijcard.2014.12.137
   PubMed Web of Science ®Google Scholar
• Holmager P, Egstrup M, Gustafsson I, et al. Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve. BMC Cardiovasc Disord. 2017;17(1):22. doi: 10.1186/s12872-016-0437-6
   PubMedGoogle Scholar
• Trippel TD, Mende M, Düngen HD, et al. The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study. ESC Heart Fail. 2021;8(2):829–841. doi: 10.1002/ehf2.13174
   PubMed Web of Science ®Google Scholar
• Gruson D, Mancini M, Ahn SA, et al. Galectin-3 testing: validity of a novel automated assay in heart failure patients with reduced ejection fraction. Clin Chim Acta. 2014;429:189–193. doi: 10.1016/j.cca.2013.12.017
   PubMed Web of Science ®Google Scholar
• Ianoș RD, Pop C, Iancu M, et al. Diagnostic performance of serum biomarkers fibroblast growth factor 21, galectin-3 and copeptin for heart failure with preserved ejection fraction in a sample of patients with type 2 diabetes mellitus. Diagn (Basel). 2021;11(9):1577. doi: 10.3390/diagnostics11091577
   PubMedGoogle Scholar
• de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43(1):60–68. doi: 10.3109/07853890.2010.538080
   PubMed Web of Science ®Google Scholar
• AbouEzzeddine OF, McKie PM, Dunlay SM, et al. Suppression of tumorigenicity 2 in heart failure with preserved ejection fraction. J Am Heart Assoc. 2017;6(2):e004382. doi: 10.1161/JAHA.116.004382
   PubMed Web of Science ®Google Scholar
• Beetler DJ, Bruno KA, Di Florio DN, et al. Sex and age differences in sST2 in cardiovascular disease. Front Cardiovasc Med. 2023;9:1073814. doi: 10.3389/fcvm.2022.1073814
   PubMed Web of Science ®Google Scholar
• Kim AJ, Ro H, Kim H, et al. Soluble ST2 and galectin-3 as predictors of chronic kidney disease progression and outcomes. Am J Nephrol. 2021;52(2):119–130. doi: 10.1159/000513663
   PubMed Web of Science ®Google Scholar
• Li M, Duan L, Cai Y, et al. Prognostic value of soluble suppression of tumorigenesis-2 (sST2) for cardiovascular events in coronary artery disease patients with and without diabetes mellitus. Cardiovasc Diabetol. 2021;20(1):49. doi: 10.1186/s12933-021-01244-3
   PubMed Web of Science ®Google Scholar
• Lin YH, Zhang RC, Hou LB, et al. Distribution and clinical association of plasma soluble ST2 during the development of type 2 diabetes. Diabet Res Clin Pract. 2016;118:140–145. doi: 10.1016/j.diabres.2016.06.006
   PubMed Web of Science ®Google Scholar
• Hughes MF, Appelbaum S, Havulinna AS, et al. FINRISK and BiomarCaRE investigators. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality. Heart. 2014;100(21):1715–1721. doi: 10.1136/heartjnl-2014-305968
   PubMed Web of Science ®Google Scholar
• Johann K, Kleinert M, Klaus S. The role of GDF15 as a myomitokine. Cells. 2021;10(11):2990. doi: 10.3390/cells10112990
   PubMed Web of Science ®Google Scholar
• Aguilar-Recarte D, Barroso E, Gumà A, et al. GDF15 mediates the metabolic effects of PPARβ/δ by activating AMPK. Cell Rep. 2021;36(6):109501. doi: 10.1016/j.celrep.2021.109501
   PubMed Web of Science ®Google Scholar
• Breit SN, Brown DA, Tsai VW. The GDF15-GFRAL pathway in health and metabolic disease: friend or foe? Annu Rev Physiol. 2021;83(1):127–151. doi: 10.1146/annurev-physiol-022020-045449
   PubMedGoogle Scholar
• Laurens C, Parmar A, Murphy E, et al. Growth and differentiation factor 15 is secreted by skeletal muscle during exercise and promotes lipolysis in humans. JCI Insight. 2020;5(6):e131870. doi: 10.1172/jci.insight.131870
   PubMed Web of Science ®Google Scholar
• Tsai VWW, Husaini Y, Sainsbury A, et al. The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 2018;28(3):353–368. doi:10.1016/j.cmet.2018.07.018
   PubMed Web of Science ®Google Scholar
• Wang D, Day EA, Townsend LK, et al. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nat Rev Endocrinol. 2021;17(10):592–607. doi: 10.1038/s41574-021-00529-7
   PubMed Web of Science ®Google Scholar
• Berezin AE. Diabetes mellitus related biomarker: the predictive role of growth-differentiation factor-15. Diabetes Metab Syndr. 2016;10(1 Suppl 1):S154–7. doi: 10.1016/j.dsx.2015.09.016
   PubMedGoogle Scholar
• Wang Z, Yang F, Ma M, et al. The impact of growth differentiation factor 15 on the risk of cardiovascular diseases: two-sample mendelian randomization study. BMC Cardiovasc Disord. 2020;20(1):462. doi: 10.1186/s12872-020-01744-2
   PubMed Web of Science ®Google Scholar
• Li T, Chen Y, Ye T, et al. Association of growth differentiation factor-15 level with adverse outcomes in patients with stable coronary artery disease: a meta-analysis. Atheroscler Plus. 2021;47:1–7. doi: 10.1016/j.athplu.2021.11.003
   PubMedGoogle Scholar
• Gürgöze MT, van Vark LC, Baart SJ, et al. Multimarker analysis of serially measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, creatinine, and prognosis in acute heart failure. Circ Heart Fail. 2023;16(1):e009526. doi: 10.1161/CIRCHEARTFAILURE.122.009526
   PubMed Web of Science ®Google Scholar
• Hongisto M, Lassus J, Tarvasmäki T, et al. CardShock study investigators and the GREAT network. Mortality risk prediction in elderly patients with cardiogenic shock: results from the CardShock study. ESC Heart Fail. 2021;8(2):1398–1407. doi: 10.1002/ehf2.13224
   PubMed Web of Science ®Google Scholar
• Wiklund FE, Bennet AM, Magnusson PK, et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell. 2010;9(6):1057–1064. doi: 10.1111/j.1474-9726.2010.00629.x
   PubMed Web of Science ®Google Scholar
• Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, et al. Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: a hidden treasure. J Diabetes. 2022;14(12):806–814. doi: 10.1111/1753-0407.13334
   PubMed Web of Science ®Google Scholar
• Coll AP, Chen M, Taskar P, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020;578(7795):444–448. doi: 10.1038/s41586-019-1911-y
   PubMed Web of Science ®Google Scholar
• Sen T, Li J, Neuen BL, et al. Association between circulating GDF-15 and cardio-renal outcomes and effect of Canagliflozin: results from the CANVAS trial. J Am Heart Assoc. 2021;10(23):e021661. doi: 10.1161/JAHA.121.021661
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Murthy AC, Lee YH, et al. Mechanisms of sodium-glucose cotransporter 2 inhibition: insights from large-scale proteomics. Diabetes Care. 2020;43(9):2183–2189. doi: 10.2337/dc20-0456
   PubMed Web of Science ®Google Scholar
• Xie S, Li Q, Luk AOY, et al. Major adverse cardiovascular events and mortality prediction by circulating GDF-15 in patients with type 2 diabetes: a systematic review and meta-analysis. Biomolecules. 2022;12(7):934. doi: 10.3390/biom12070934
   PubMed Web of Science ®Google Scholar
• Carlsson AC, Nowak C, Lind L, et al. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. Ups J Med Sci. 2020;125(1):37–43. doi: 10.1080/03009734.2019.1696430
   PubMed Web of Science ®Google Scholar
• Nair V, Robinson-Cohen C, Smith MR, et al. Growth differentiation factor-15 and risk of CKD progression. J Am Soc Nephrol. 2017;28(7):2233–2240. doi: 10.1681/ASN.2016080919
   PubMed Web of Science ®Google Scholar
• Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102
   PubMed Web of Science ®Google Scholar
• Frikke-Schmidt H, Hultman K, Galaske JW, et al. GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice. Molecular Metabolism. 2019;21:13–21. doi: 10.1016/j.molmet.2019.01.003
   PubMed Web of Science ®Google Scholar
• Liu S, Cui F, Ning K, et al. Role of irisin in physiology and pathology. Front Endocrinol. 2022;13:962968. doi: 10.3389/fendo.2022.962968
   PubMed Web of Science ®Google Scholar
• Kim H, Wrann CD, Jedrychowski M, et al. Irisin mediates effects on bone and fat via αv integrin receptors. Cell. 2018;175(7):1756–1768.e17. doi: 10.1016/j.cell.2018.10.025
   PubMed Web of Science ®Google Scholar
• Hu X, Wang Z, Wang W, et al. Irisin as an agent for protecting against osteoporosis: a review of the current mechanisms and pathways. J Adv Res. 2023;S2090-1232(23). doi: 10.1016/j.jare.2023.09.001
   Google Scholar
• Qiongyue Z, Xin Y, Meng P, et al. Post-treatment with irisin attenuates acute kidney injury in sepsis mice through anti-ferroptosis via the SIRT1/Nrf2 pathway. Front Pharmacol. 2022;13:857067. doi: 10.3389/fphar.2022.857067
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Anastasilakis AD, Efstathiadou ZA, et al. Irisin in metabolic diseases. Endocrine. 2018;59(2):260–274. doi: 10.1007/s12020-017-1476-1
   PubMed Web of Science ®Google Scholar
• Zhu B, Wang B, Zhao C, et al. Irisin regulates cardiac responses to exercise in health and diseases: a narrative review. J Cardiovasc Transl Res. 2023;16(2):430–442. doi: 10.1007/s12265-022-10310-4
   PubMed Web of Science ®Google Scholar
• Ho MY, Wang CY. Role of Irisin in myocardial infarction, heart failure, and cardiac hypertrophy. Cells. 2021;10(8):2103. doi: 10.3390/cells10082103
   PubMed Web of Science ®Google Scholar
• Li J, Xie S, Guo L, et al. Irisin: linking metabolism with heart failure. Am J Transl Res. 2020;12(10):6003–6014.
   PubMed Web of Science ®Google Scholar
• Berezin AA, Obradovic AB, Fushtey IM, et al. Low plasma levels of irisin predict acutely decompensated heart failure in type 2 diabetes mellitus patients with chronic heart failure. J Cardiovasc Dev Dis. 2023;10(4):136. doi: 10.3390/jcdd10040136
   PubMed Web of Science ®Google Scholar
• Tomasello L, Pitrone M, Guarnotta V, et al. Irisin: a possible marker of adipose tissue dysfunction in obesity. Int J Mol Sci. 2023;24(15):12082. doi: 10.3390/ijms241512082
   PubMed Web of Science ®Google Scholar
• Berezin AA, Obradovic Z, Novikov EV, et al. Interplay between myokine profile and glycemic control in type 2 diabetes mellitus patients with heart failure. Diagn (Basel). 2022;12(12):2940. doi: 10.3390/diagnostics12122940
   PubMedGoogle Scholar
• Berezin AA, Fushtey IM, Pavlov SV, et al. Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus. Mol Biomed. 2022;3(1):34. doi: 10.1186/s43556-022-00096-x
   PubMedGoogle Scholar
• Berezin AA, Lichtenauer M, Boxhammer E, et al. Serum levels of irisin predict cumulative clinical outcomes in heart failure patients with type 2 diabetes mellitus. Front physiol. 2022;13:922775. doi: 10.3389/fphys.2022.922775
   PubMed Web of Science ®Google Scholar
• Berezin AA, Lichtenauer M, Boxhammer E, et al. Discriminative value of serum Irisin in prediction of heart failure with different phenotypes among patients with type 2 diabetes mellitus. Cells. 2022;11(18):2794. doi: 10.3390/cells11182794
   PubMed Web of Science ®Google Scholar
• Berezina TA, Fushtey IM, Berezin AA, et al. Predictors of kidney function outcomes and their relation to SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus who had chronic heart failure. Adv Ther. 2024;41(1):292–314. doi: 10.1007/s12325-023-02683-y
   PubMed Web of Science ®Google Scholar
• Marczuk N, Cecerska-Heryć E, Jesionowska A, et al. Adropin - physiological and pathophysiological role. Postepy Higieny i Medycyny Doswiadczalnej. 2016;70:981–988. doi: 10.5604/17322693.1220082
   Web of Science ®Google Scholar
• Wong CM, Wang Y, Lee JT, et al. Adropin is a brain membrane-bound protein regulating physical activity via the NB-3/Notch signaling pathway in mice. J Biol Chem. 2014;289(37):25976–25986. doi: 10.1074/jbc.M114.576058
   PubMed Web of Science ®Google Scholar
• Aydin S, Kuloglu T, Aydin S. Copeptin, adropin and irisin concentrations in breast milk and plasma of healthy women and those with gestational diabetes mellitus. Peptides. 2013;47:66–70. doi: 10.1016/j.peptides.2013.07.001
   PubMed Web of Science ®Google Scholar
• Ganesh Kumar K, Zhang J, Gao S, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring). 2012;20(7):1394–1402. doi: 10.1038/oby.2012.31
   PubMed Web of Science ®Google Scholar
• Thapa D, Xie B, Manning JR, et al. Adropin reduces blood glucose levels in mice by limiting hepatic glucose production. Physiol Rep. 2019;7(8):e14043. doi: 10.14814/phy2.14043
   PubMed Web of Science ®Google Scholar
• Ying T, Wu L, Lan T, et al. Adropin inhibits the progression of atherosclerosis in ApoE-/-/Enho-/- mice by regulating endothelial-to-mesenchymal transition. Cell Death Discov. 2023;9(1):402. doi: 10.1038/s41420-023-01697-3
   PubMed Web of Science ®Google Scholar
• Sato K, Yamashita T, Shirai R, et al. Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation. Int J Mol Sci. 2018;19(5):1293. doi: 10.3390/ijms19051293
   PubMed Web of Science ®Google Scholar
• Wei W, Liu H, Qiu X, et al. The association between serum adropin and carotid atherosclerosis in patients with type 2 diabetes mellitus: a cross‑sectional study. Diabetol Metab Syndr. 2022;14(1):27. doi: 10.1186/s13098-022-00796-y
   PubMed Web of Science ®Google Scholar
• Wu L, Fang J, Chen L, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med. 2014;52(5):751–758. doi: 10.1515/cclm-2013-0844
   PubMed Web of Science ®Google Scholar
• Soltani S, Beigrezaei S, Malekahmadi M, et al. Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies. BMC Endocr Disord. 2023;23(1):73. doi: 10.1186/s12902-023-01327-0
   PubMed Web of Science ®Google Scholar
• Jurrissen TJ, Ramirez-Perez FI, Cabral-Amador FJ, et al. Role of adropin in arterial stiffening associated with obesity and type 2 diabetes. Am J Physiol Heart Circ Physiol. 2022;323(5):H879–H891. doi: 10.1152/ajpheart.00385.2022
   PubMed Web of Science ®Google Scholar
• Vivek K, Reddy EP, Thangappazham B, et al. Maternal adropin levels in patients with gestational diabetes mellitus: a systematic review and meta-analysis. Gynecol Endocrinol. 2022;38(2):105–109. doi: 10.1080/09513590.2021.1963703
   PubMed Web of Science ®Google Scholar
• Es-Haghi A, Al-Abyadh T, Mehrad-Majd H. The clinical value of serum adropin level in early detection of diabetic nephropathy. Kidney Blood Press Res. 2021;46(6):734–740. doi: 10.1159/000519173
   PubMedGoogle Scholar
• Berezina TA, Obradovic Z, Boxhammer E, et al. Adropin predicts chronic kidney disease in type 2 diabetes mellitus patients with chronic heart failure. J Clin Med. 2023;12(6):2231. doi: 10.3390/jcm12062231
   PubMed Web of Science ®Google Scholar
• Berezin AA, Obradovic Z, Fushtey IM, et al. The impact of SGLT2 inhibitor dapagliflozin on adropin serum levels in men and women with type 2 diabetes mellitus and chronic heart failure. Biomedicines. 2023;11(2):457. doi: 10.3390/biomedicines11020457
   PubMed Web of Science ®Google Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8(3):235–253. doi: 10.1038/nrd2792
   PubMed Web of Science ®Google Scholar
• Luo Y, McKeehan WL. Stressed liver and muscle call on adipocytes with FGF21. Front Endocrinol. 2013;4:194. doi: 10.3389/fendo.2013.00194
   PubMedGoogle Scholar
• Itoh N, Ohta H, Konishi M. Endocrine FGFs: evolution, physiology, pathophysiology, and pharmacotherapy. Front Endocrinol. 2015;6:154. doi:10.3389/fendo.2015.00154
   PubMed Web of Science ®Google Scholar
• Lee S, Choi J, Mohanty J, et al. Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signaling. Nature. 2018;553(7689):501–505. doi: 10.1038/nature25010
   PubMed Web of Science ®Google Scholar
• Luo Y, Ye S, Chen X, et al. Rush to the fire: FGF21 extinguishes metabolic stress, metaflammation and tissue damage. Cytokine Growth Factor Rev. 2017;38:59–65. doi: 10.1016/j.cytogfr.2017.08.001
   PubMed Web of Science ®Google Scholar
• Guo D, Xiao L, Hu H, et al. FGF21 protects human umbilical vein endothelial cells against high glucose-induced apoptosis via PI3K/Akt/Fox3a signaling pathway. J Diabetes Complications. 2018;32(8):729–736. doi: 10.1016/j.jdiacomp.2018.05.012
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu D, Long XX, et al. The role of FGF21 in the pathogenesis of cardiovascular disease. Chin Med J (Engl). 2021;134(24):2931–2943. doi: 10.1097/CM9.0000000000001890
   PubMed Web of Science ®Google Scholar
• Choi MJ, Jung SB, Lee SE, et al. An adipocyte-specific defect in oxidative phosphorylation increases systemic energy expenditure and protects against diet-induced obesity in mouse models. Diabetologia. 2020;63(4):837–852. doi: 10.1007/s00125-019-05082-7
   PubMed Web of Science ®Google Scholar
• Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020;16(11):654–667. doi: 10.1038/s41574-020-0386-0
   PubMed Web of Science ®Google Scholar
• Shen Y, Ma X, Zhou J, et al. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol. 2013;12(1):124.
   PubMedGoogle Scholar
• Chee Y, Toh GL, Lim CJ, et al. Sex modifies the association of fibroblast growth factor 21 with subclinical carotid atherosclerosis. Front Cardiovasc Med. 2021;8:627691. doi: 10.3389/fcvm.2021.627691
   PubMed Web of Science ®Google Scholar
• Sommakia S, Almaw NH, Lee SH, et al. FGF21 (fibroblast growth factor 21) defines a potential cardiohepatic signaling circuit in end-stage heart failure. Circ Heart Fail. 2022;15(3):e008910. doi: 10.1161/CIRCHEARTFAILURE.121.008910
   PubMed Web of Science ®Google Scholar
• Haberka M, Machnik G, Kowalówka A, et al. Epicardial, paracardial, and perivascular fat quantity, gene expressions, and serum cytokines in patients with coronary artery disease and diabetes. Pol Arch Intern Med. 2019;129(11):738–746. doi: 10.20452/pamw.14961
   PubMedGoogle Scholar
• Drexler S, Cai C, Hartmann AL, et al. Intestinal BMP-9 locally upregulates FGF19 and is down-regulated in obese patients with diabetes. Mol Cell Endocrinol. 2023;570:111934. doi: 10.1016/j.mce.2023.111934
   PubMed Web of Science ®Google Scholar
• Yang K, Wang H, Wei R, et al. High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes. Acta Diabetol. 2021;58(5):595–602. doi: 10.1007/s00592-020-01660-z
   PubMed Web of Science ®Google Scholar
• Hu X, Ma X, Pan X, et al. Fibroblast growth factor 23 is associated with the presence of coronary artery disease and the number of stenotic vessels. Clin Exp Pharmacol Physiol. 2015;42(11):1152–1157. doi: 10.1111/1440-1681.12467
   PubMed Web of Science ®Google Scholar
• Li Q, Zhang Y, Ding D, et al. Association between serum fibroblast growth factor 21 and mortality among patients with coronary artery disease. J Clin Endocrinol Metab. 2016;101(12):4886–4894. doi: 10.1210/jc.2016-2308
   PubMed Web of Science ®Google Scholar
• Brandenburg VM, Kleber ME, Vervloet MG, et al. Fibroblast growth factor 23 (FGF23) and mortality: the ludwigshafen risk and cardiovascular health study. Atherosclerosis. 2014;237(1):53–59. doi: 10.1016/j.atherosclerosis.2014.08.037
   PubMed Web of Science ®Google Scholar
• Qin Z, Liu X, Song M, et al. Fibroblast growth factor 23 as a predictor of cardiovascular and all-cause mortality in prospective studies. Atherosclerosis. 2017;261:1–11. doi: 10.1016/j.atherosclerosis.2017.03.042
   PubMed Web of Science ®Google Scholar
• Gu L, Jiang W, Jiang W, et al. Elevated serum FGF21 levels predict heart failure during hospitalization of STEMI patients after emergency percutaneous coronary intervention. PeerJ. 2023;11:e14855. doi: 10.7717/peerj.14855
   PubMed Web of Science ®Google Scholar
• Fan L, Gu L, Yao Y, et al. Elevated serum fibroblast growth factor 21 is relevant to heart failure patients with reduced ejection fraction. Comput Math Meth Med. 2022;2022:1–6. doi: 10.1155/2022/7138776
   Web of Science ®Google Scholar
• Wu G, Wu S, Yan J, et al. Fibroblast growth factor 21 predicts short-term prognosis in patients with acute heart failure: a prospective cohort study. Front Cardiovasc Med. 2022;9:834967. doi: 10.3389/fcvm.2022.834967
   PubMed Web of Science ®Google Scholar
• Chou RH, Huang PH, Hsu CY, et al. Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction. Sci Rep. 2016;6(1):33953.
   PubMedGoogle Scholar
• Tucker W, McClelland RL, Allison MA, et al. The association of circulating fibroblast growth factor 21 levels with incident heart failure: the multi-ethnic study of atherosclerosis. Metabolism. 2023;143:155535. doi: 10.1016/j.metabol.2023.155535
   PubMed Web of Science ®Google Scholar
• Zhou Q, Chen L, Tang M, et al. Apelin/APJ system: a novel promising target for anti-aging intervention. Clin Chim Acta. 2018;487:233–240. doi: 10.1016/j.cca.2018.10.011
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang L, Li P, et al. Apelin/APJ system in inflammation. Int Immunopharmacol. 2022;109:108822. doi: 10.1016/j.intimp.2022.108822
   PubMed Web of Science ®Google Scholar
• Cheng J, Luo X, Huang Z, et al. Apelin/APJ system: a potential therapeutic target for endothelial dysfunction-related diseases. J Cell Physiol. 2019;234(8):12149–12160. doi: 10.1002/jcp.27942
   PubMed Web of Science ®Google Scholar
• Pang B, Jiang YR, Xu JY, et al. Apelin/ELABELA-APJ system in cardiac hypertrophy: regulatory mechanisms and therapeutic potential. Eur J Pharmacol. 2023;949:175727. doi: 10.1016/j.ejphar.2023.175727
   PubMed Web of Science ®Google Scholar
• Yang Y, Chen M, Qiu Y, et al. The Apelin/APLNR system modulates tumor immune response by reshaping the tumor microenvironment. Gene. 2022;834:146564. doi: 10.1016/j.gene.2022.146564
   PubMed Web of Science ®Google Scholar
• Huang J, Kang S, Park SJ, et al. Apelin protects against liver X receptor-mediated steatosis through AMPK and PPARα in human and mouse hepatocytes. Cell Signal. 2017;39:84–94. doi: 10.1016/j.cellsig.2017.08.003
   PubMed Web of Science ®Google Scholar
• Ma WY, Yu TY, Wei JN, et al. Plasma apelin: a novel biomarker for predicting diabetes. Clin Chim Acta. 2014;435:18–23. doi: 10.1016/j.cca.2014.03.030
   PubMed Web of Science ®Google Scholar
• Erdem G, Dogru T, Tasci I, et al. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2008;116(5):289–292. doi: 10.1055/s-2007-1004564
   PubMed Web of Science ®Google Scholar
• Nagib AM, El-Diasty A, El Husseny MA, et al. Apelin and new-onset diabetes after transplant in living kidney allograft recipients. Exp Clin Transplant. 2015;13(4): 319–323. PMID: 26295182.
   PubMed Web of Science ®Google Scholar
• Hosny SS, Nasr MS, Ibrahim RH, et al. Relation between plasma apelin level and peripheral neuropathy in type 2 diabetic patients. Diabetes Metab Syndr. 2019;13(1):626–629. doi: 10.1016/j.dsx.2018.11.027
   PubMed Web of Science ®Google Scholar
• Mund C, Kellellu CK, Rattan R, et al. Study of serum apelin and insulin resistance in type 2 diabetes mellitus patients with or without obesity. Cureus. 2023;15(8):e43401. doi: 10.7759/cureus.43401
   PubMed Web of Science ®Google Scholar
• Berezin AA, Fushtey IM, Berezin AE. Discriminative utility of apelin-to-NT-Pro-brain natriuretic peptide ratio for heart failure with preserved ejection fraction among type 2 diabetes mellitus patients. J Cardiovasc Dev Dis. 2022;9(1):23. doi: 10.3390/jcdd9010023
   PubMed Web of Science ®Google Scholar
• García-Hermoso A, Ramírez-Vélez R, Díez J, et al. Exercise training-induced changes in exerkine concentrations may be relevant to the metabolic control of type 2 diabetes mellitus patients: a systematic review and meta-analysis of randomized controlled trials. J Sport Health Sci. 2023;12(2):147–157. doi: 10.1016/j.jshs.2022.11.003
   PubMed Web of Science ®Google Scholar
• Robillard S, Trân K, Lachance MS, et al. Apelin prevents diabetes-induced poor collateral vessel formation and blood flow reperfusion in ischemic limb. Front Cardiovasc Med. 2023;10:1191891. doi: 10.3389/fcvm.2023.1191891
   PubMed Web of Science ®Google Scholar
• Berezin AA, Fushtey IM, Berezin AE. The effect of SGLT2 inhibitor dapagliflozin on serum levels of apelin in T2DM patients with heart failure. Biomedicines. 2022;10(7):1751. doi: 10.3390/biomedicines10071751
   PubMed Web of Science ®Google Scholar
• Diallo A, Carlos-Bolumbu M, Galtier F. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis. Acta Diabetol. 2023;60(12):1651–1662. doi: 10.1007/s00592-023-02154-4
   PubMed Web of Science ®Google Scholar
• Belli M, Barone L, Bellia A, et al. Treatment of HFpEF beyond the SGLT2-is: does the addition of GLP-1 RA improve cardiometabolic risk and outcomes in diabetic patients? Int J Mol Sci. 2022;23(23):14598. doi: 10.3390/ijms232314598
   PubMed Web of Science ®Google Scholar
• Giugliano D, Meier JJ, Esposito K. Heart failure and type 2 diabetes: from cardiovascular outcome trials, with hope. Diab Obes Metab. 2019;21(5):1081–1087. doi: 10.1111/dom.13629
   PubMed Web of Science ®Google Scholar
• Giugliano D, Maiorino MI, Longo M, et al. Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials. Endocrine. 2019;65(1):15–24. doi: 10.1007/s12020-019-01931-y
   PubMed Web of Science ®Google Scholar
• Miyoshi H, Oishi Y, Mizuguchi Y, et al. Association of left atrial reservoir function with left atrial structural remodeling related to left ventricular dysfunction in asymptomatic patients with hypertension: evaluation by two-dimensional speckle-tracking echocardiography. Clin Exp Hypertens. 2015;37(2):155–165. doi: 10.3109/10641963.2014.933962
   PubMed Web of Science ®Google Scholar
• Mu G, Wang W, Liu C, et al. Combination of SVI/S’ and diagnostic scores for heart failure with preserved ejection fraction. Clin Exp Pharmacol Physiol. 2023;50(8):677–687. doi: 10.1111/1440-1681.13782
   PubMed Web of Science ®Google Scholar
• Piccirillo G, Moscucci F, Carnovale M, et al. Glucose dysregulation and repolarization variability markers are short-term mortality predictors in decompensated heart failure. Cardiovasc Endocrinol Metab. 2022;11(3):e0264. doi: 10.1097/XCE.0000000000000264
   PubMed Web of Science ®Google Scholar
• Lazzeri C, Valente S, Chiostri M, et al. Prognostic impact of early glucose variability in acute heart failure patients: a pilot study. Intern J Cardiol. 2014;177(2):693–695. doi: 10.1016/j.ijcard.2014.09.150
   PubMed Web of Science ®Google Scholar
• Wang T, Xu J, Zhang H, et al. Triglyceride-glucose index for the detection of subclinical heart failure with preserved ejection fraction in patients with type 2 diabetes. Front Cardiovasc Med. 2023;10:1086978. doi: 10.3389/fcvm.2023.1086978
   PubMed Web of Science ®Google Scholar
• Khalaji A, Behnoush AH, Khanmohammadi S, et al. Triglyceride-glucose index and heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol. 2023;22(1):244. doi: 10.1186/s12933-023-01973-7
   PubMed Web of Science ®Google Scholar
• Yeung AM, Huang J, Pandey A, et al. Biomarkers for the diagnosis of heart failure in people with diabetes: a consensus report from diabetes technology society. Prog Cardiovasc Dis. 2023;79:65–79. doi: 10.1016/j.pcad.2023.05.002
   PubMed Web of Science ®Google Scholar